Erlotinib beyond progression study: Randomized phase II study comparing chemotherapy plus erlotinib with chemotherapy alone in EGFR TKI-responsive, advanced non-small cell lung cancer (NSCLC) that subsequently progresses.
Year: 2011
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: B. Halmos, P. Fu, N. A. Pennell, G. A. Otterson, T. Mekhail, M. R. Snell, J. P. Kuebler, S. M. Gadgeel, A. Conrad, A. T. Stefanski, A. Dowlati
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2567446343